Empagliflozin targeted the immune-related gene PIK3CA in type 2 diabetes mellitus treatment: network pharmacology analysis and experimental evidence
Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) is linked to elevated blood glucose due to insulin resistance. Empagliflozin has demonstrated efficacy in T2DM management, with potential immune-modulatory effects. This study aimed to investigate the immune-related mechanisms of empagliflozin in T2DM treatment.
METHODS: Gene expression profiles were obtained from common databases, and immune-related differentially expressed genes (IRDEGs) were identified using the "limma" R package. The STRING database and Cytoscape software were utilized to construct a protein-protein interaction network and identify key IRDEGs. Molecular docking was performed to predict the interaction between empagliflozin and PIK3CA. Pathways related to PIK3CA were explored using GSEA, and relationship of PIK3CA with immune cells was analyzed using single-cell RNA sequencing analysis. The effects of empagliflozin on high glucose-induced RAW264.7 macrophages and PI3K/AKT signaling were assessed using CCK-8, fluorescence detection, qRT-PCR, and Western blotting.
RESULTS: We identified 109 IRDEGs in T2DM, with PIK3CA as a key gene. Empagliflozin showed binding affinity to PIK3CA, which was linked to immune cell interactions and inflammatory responses. Single-cell RNA sequencing analysis revealed the interaction of PIK3CA with macrophages. In high glucose-induced RAW264.7 macrophages, PIK3CA expression was elevated. Empagliflozin ameliorated the high glucose-induced cell injury and inhibited the expression of…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.